Pharmaceutical companies in India are globally recognised for their medical advancements. Today, we will introduce you to the second-largest pharmaceutical company in India based on market cap. From its beginnings back in 1990 as a small research centre to becoming a global supplier in 100 nations, Divi’s Laboratories has a market cap of ₹1,36,584 Crores.
Ready to read about the revolutionary growth history of Divis Labs?
Let’s begin!
From 1990 to Today: The Remarkable History of Divi’s Laboratories Ltd.
It all began with a vision in 1990. Divi’s Pharma started its journey as Divi’s Research Centre (DRC), a small spark igniting what would become a global powerhouse. In 1995, the first significant milestone was set with the establishment of their first manufacturing facility (Unit-1) near Hyderabad. The groundwork was laid, and the future was bright.
By 2000, Divi’s Labs was ready to show the world its potential. They proudly passed their first USFDA inspection, marking the beginning of a series of global recognitions. The new millennium also saw the start of their second manufacturing facility (Unit-2) near Vishakhapatnam in 2002.
The story continued to unfold.
In 2003, Divi’s Labs made a significant leap by getting listed on the Indian Stock Exchange. This was just the beginning. By 2007, the company set up a state-of-the-art Nutraceuticals facility at Unit 2. They were all set to broaden their horizons in health supplements.
2008 brought a fresh wave of success with their first MFDS (Korea) inspection. This was followed by the establishment of a new research centre in Hyderabad in 2010. The same year, they celebrated another triumph: a new corporate office in Hyderabad.
2013 was a landmark year with several noteworthy achievements. They received their first Slovenian Medicines Agency inspection for Unit-II and were honoured with the “Premier Trading House” certificate by the Ministry of Commerce & Industry, Govt. of India. In 2014, Divis Labs’ revenue surpassed the sales of 2500 crores, with a notable growth rate of 18%. They also achieved the milestone of 8700 employees and welcomed their first COFEPRIS inspection.
In 2015, Divi’s laboratories owner inaugurated a new corporate office in Hyderabad. The momentum carried through to 2016. Divi’s Pharma’s revenue exceeded sales revenue of INR 3,700 crores with a 22% growth rate and celebrated its first Anvisa (Brazil) inspection.
The company’s growth story continued to gather pace. In 2017, Divi’s Labs reached a milestone of 11,000 employees. It became one of the largest employers in Telangana and Andhra Pradesh.
They also joined the elite ranks of the top 3 API manufacturers globally and among the top API companies in Hyderabad.
By 2018, Divi’s market capital soared to $5 billion. They commissioned 10 new production blocks and expanded their product portfolio to over 30 items. The 5th USFDA inspection of Unit-1 further validated their excellence.
The following years were equally groundbreaking. In 2019, the company made an additional investment of $250 million to expand production blocks in Unit I and Unit II. They also faced their 7th USFDA inspection at Unit-2 and their 6th inspection at Unit-1.
2020 brought new challenges and achievements. Divi’s Labs commissioned new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II. The year also marked their 8th USFDA inspection at Unit 2.
As the story unfolds, 2021 was a year of significant milestones. Divi’s proudly broke ground on a new manufacturing plant in Kakinada, adding another chapter to their success story.
Their journey continues, driven by a passion for quality and a commitment to making a difference worldwide. As of today, Divi’s Laboratories Ltd stands as the second-largest pharmaceutical company in India based on market cap.
Divi’s Labs: Second Largest Pharma Company in India
Divi’s has been a leading name in active pharmaceutical ingredients since 1990. The company specialises in APIs, intermediates, and nutraceutical ingredients. It offers high-quality products to over 100 countries. Recently, Divi reached a milestone as one of the top three API manufacturers in the world.
Wondering what does Divi’s Labs do?
Divi’s Laboratories specialises in manufacturing active pharmaceutical ingredients (APIs) and intermediates.
- They produce high-quality APIs used in various medications.
- They supply chemical compounds that are used in the production of APIs.
- It offers custom manufacturing services for APIs tailored to pharmaceutical companies’ specific needs.
Business Segments of Divi’s Laboratories
Divi’s Laboratories specialises in three key areas:
Manufacturing Generic APIs, producing Nutraceutical ingredients, and offering Custom-synthesis for the Pharma Industry. The company was founded with a clear goal: to become a reliable supplier of APIs and achieve leadership through sustainable chemistry.
Divi’s Labs Net Worth– $8.6B
Divi’s Laboratories Ltd Business Operations 2024
- Operates the world’s largest API manufacturing facility.
- Employs ~400 scientists across three R&D centres.
- ~2,100 employees are dedicated to Quality Assurance and Quality Control.
- R&D focuses on developing cost-effective, non-infringing processes with continuous improvement.
- Divis Labs operates two manufacturing sites that are compliant with global regulatory standards. They are capable of producing from 10s of kilos to 1000s of tons.
Divi’s Laboratories Products:
- Generic APIs: Divi’s is a major global producer of generic APIs.
Some key products are:
- Naproxen
- Dextromethorphan
- Gabapentin
- Levetiracetam
- Valsartan
- Pregabalin
- Phenylephrine
- Nutraceutical Ingredients: They also make ingredients for health supplements, including:
- Beta Carotene
- Lutein
- Astaxanthin
- Lycopene
- Vitamin D3
- Vitamin A
- Custom Synthesis: Divi’s Pharma provides custom manufacturing services for APIs.
Their products are used in many types of medicines, like those for depression, cancer, high blood pressure, seizures, and viruses.
Divi’s Labs’ CSR Highlights 2024
As part of their ongoing efforts to support communities, Divi’s has recently announced that the company will providemeals to flood victims over the next five days. A huge amount of ₹2.5 crore is allocated for this vital relief effort. In collaboration with the Hare Krishna Charitable Foundation, Divi’s Labs is serving three times meals to over 170,000 individuals affected by the floods in Vijayawada. This initiative reflects Divi’s dedication to helping those in need.
Here is a look at the CSR efforts of Divis Labs in 2024:
Key Programs and Stats
- Child Empowerment: 15,000 children benefited
- Preventive Healthcare: 400,000 people benefited
- Safe Drinking Water: 215,000 people benefited
- Plantation Drives: 135,000 saplings planted
- Animal Welfare: 50,000 people benefited
- Village Development: 80,000 people benefited
Environmental Initiatives
Divi’s is involved in various initiatives like green belt development and carbon footprint reduction. They focus on effective water, energy, and waste management to minimise their environmental impact.
- Green Belt Development
- Reducing Carbon Footprint
- Water Management
- Energy Management
- Waste Management
If you’re looking to invest in the pharma industry, Divi’s Laboratories is a top choice among the top 10 pharma companies in India. However, be sure to conduct thorough research before investing.
FAQs| Divi’s Laboratories
Yes, Divis Laboratories Ltd is a reputable company known for its strong financial performance. As of Sep 5th, 2024, it is the 2n largest pharma company in India.
Yes, Divis Laboratories is a multinational corporation with a significant presence in over 100 countries.
Divis Laboratories was founded by Dr. Murali Krishna Prasad Divi, who is also the owner and current MD.
Divis Laboratories ranks as the second largest pharmaceutical company in India by market capitalization.
The headquarters of Divis Laboratories is located in Hyderabad.
Dr. Murali Krishna Prasad Divi is the founder of Divis Laboratories.
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.